What is it about?
Relations between inhaled therapy, cardiovascular risk and prognosis in patients with COPD are complex. Globally, the benefit-risk ratio of inhaled bronchodilators +/- corticosteroids appears largely favorable. Studies in subgroups at risk are needed.
Featured Image
Read the Original
This page is a summary of: Inhaled therapy, cardiovascular risk and benefit–risk considerations in COPD: innocent until proven guilty, orvice versa?, European Respiratory Journal, February 2023, European Respiratory Society (ERS),
DOI: 10.1183/13993003.02135-2022.
You can read the full text:
Contributors
Be the first to contribute to this page
